The purpose of this study is to evaluate how well LY3316531 is tolerated and what side effects may occur in healthy participants and participants with psoriasis. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm).
This is a three-part study. Participants will enroll in only one part. Parts A and B are for healthy participants and Part C is for participants with psoriasis. Participation could last between 16 and 57 weeks.
|Condition or disease||Intervention/treatment||Phase|
|Psoriasis||Drug: LY3316531 – IV Drug: LY3316531 – SC Drug: Placebo – IV Drug: Placebo – SC||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||102 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Primary Purpose:||Basic Science|
|Official Title:||A Phase 1 Randomized, Placebo-Controlled Study of LY3316531 in Healthy Subjects and an Open-Label, Single-Dose Study in Patients With Psoriasis|
|Actual Study Start Date :||January 30, 2018|
|Estimated Primary Completion Date :||February 2019|
|Estimated Study Completion Date :||September 2019|